The 2025 European Society for Medical Oncology (ESMO) Annual Meeting is fast approaching. The global oncology community is gearing up for another momentous gathering of leading minds, data and innovation, promising to showcase the latest advancements in cancer research, care delivery and international collaboration.
This year’s congress will take place on 17th–21st October in Berlin, Germany and touchONCOLOGY be on site bringing you expert highlights, key takeaways and specialty round-ups. Keep an eye on www.touchONCOLOGY.com, along with our social media channels, for the freshest ESMO25 coverage.
Abstracts are now available here!
What to expect
- Thousands of abstracts spanning basic, translational and clinical research. For the full list of abstract submission categories click here
- Oral abstract sessions, rapid-fire presentations and clinical symposia
- Plenary lectures and Presidential symposiums from leading figures in oncology
- Debates, educational sessions and poster discussions
- Special sessions focusing on emerging fields (e.g. precision medicine, immunotherapy, molecular biomarkers, health equity)
- Multidisciplinary and international collaborations tackling global challenges in cancer care
Hot topics to watch
In the run-up to ESMO 2025, several thematic areas are already generating buzz:
- Precision oncology & biomarkers – How to tailor treatments more effectively
- Immunotherapy & novel agents – New combinations, resistance mechanisms and biomarkers of response
- Real-world evidence & health equity – Bridging gaps between trials and everyday practice
- AI, digital health & diagnostics – Tools for improving early detection, decision support, and patient monitoring
- Global oncology & access initiatives – Strategies to extend innovations to underserved regions
These themes will intersect across tumour types, clinical settings and care pathways – making ESMO a focal point for integrative thinking and fresh perspectives.
For more information, visit the official ESMO Congress website
Disclosure: This article was created by the touchONCOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by huhttps://www.asco.org/man editors. No funding was received in the publication of this article.
Cite: ESMO25: The countdown is on! touchONCOLOGY. September 30th, 2025
Related content
- Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer
- Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer
- Transarterial chemoembolization with lenvatinib and pembrolizumab showed improvement in progression-free survival for hepatocellular carcinoma
SIGN UP to touchONCOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
